Skip to main content

Table 3 Study population and treatment group characteristics

From: Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema

  Home-based
pdC1-INH (N = 20)
Home-based
icatibant (N = 11)
Hospital-based pdC1-INH (N = 8) Overall (N = 39)
Gender, N (%)
 Female 13 (65.0) 8 (72.7) 5 (62.5) 26 (66.6)
 Male 7 (35.0) 3 (27.3) 3 (37.5) 13 (33.4)
Age, mean (±SD) 33.0 (±18.7) 37.0 (±11.7) 31.0 (±20.4) 33.7 (±17.1)
Disease severity score, mean (±SD) 7.8 (±1.7) 6.9 (±1.6) 6.6 (±1.5) 7.3 (±1.7)
  1. pdC1-INH plasma-derived C1-esterase inhibitor concentrate, SD standard deviation